| pubmed-article:16758340 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0443315 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0020852 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0279033 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0439831 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:16758340 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:16758340 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16758340 | pubmed:dateCreated | 2006-6-7 | lld:pubmed |
| pubmed-article:16758340 | pubmed:abstractText | Sixty patients (16 children, 44 adults) participated in the study aiming at evaluating: (i) IgG levels when switching patients from intravenous IgG (IVIG) infusions in hospital to subcutaneous (SCIG) self-infusions at home using the same cumulative monthly dose, (ii) protections against infections, and (iii) safety of a new, ready-to-use 16% IgG preparation. All children and 33 adults had received IVIG therapy for >6 months at enrolment. Ten adults who had been on SCIG therapy for many years served as controls. Mean serum IgG trough levels increased in the pre-IVIG children from 7.8 to 9.2 g/L (non-inferiority: p < 0.001) and in the adults from 8.6 to 8.9 g/L (non-inferiority: p < 0.001). Totally 114 respiratory tract infections occurred, 90% of them mild. One serious bacterial infection (pneumonia) was reported for one adult. The annualized rate of serious infections was 0.04 episodes/patient. In total 2297 infusions were given and 28 (1%) systemic adverse reactions occurred, none of them severe. Local tissue reactions declined over time, this being particularly distinct after 8 to 10 weeks. In conclusion, the SCIG administration route was safe. High IgG levels were easily maintained resulting in a very good protection against infections. | lld:pubmed |
| pubmed-article:16758340 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16758340 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16758340 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16758340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16758340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16758340 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16758340 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:16758340 | pubmed:issn | 0271-9142 | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:MAJJ | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:BorteMichaelM | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:AsensioOscarO | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:NiehuesTimT | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:GardulfAnnA | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:BernatowskaEw... | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:GranertCarlC | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:NicolayUweU | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:SchmidtSigune... | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:KiesslingPete... | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:SchulzeIlkaI | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:BöckAndreasA | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:HaagStefanS | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:HernándezDolo... | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:CarvalhoBeatr... | lld:pubmed |
| pubmed-article:16758340 | pubmed:author | pubmed-author:PonsJauneJ | lld:pubmed |
| pubmed-article:16758340 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16758340 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:16758340 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16758340 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16758340 | pubmed:pagination | 177-85 | lld:pubmed |
| pubmed-article:16758340 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:meshHeading | pubmed-meshheading:16758340... | lld:pubmed |
| pubmed-article:16758340 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16758340 | pubmed:articleTitle | Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. | lld:pubmed |
| pubmed-article:16758340 | pubmed:affiliation | Department of Laboratory Medicine, Section of Clinical Immunology, The Swedish Centre for Immunodeficiencies, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. ann.gardulf@ki.se | lld:pubmed |
| pubmed-article:16758340 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16758340 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16758340 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16758340 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16758340 | lld:pubmed |
